Parkman Healthcare Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.03M | Buy |
1,007,992
+7,430
| +0.7% | +$66.6K | 1.04% | 32 |
|
|
2025
Q1 | $7.5M | Buy |
1,000,562
+783,681
| +361% | +$5.88M | 0.89% | 40 |
|
|
2024
Q4 | $1.63M | Sell |
216,881
-247,167
| -53% | -$1.86M | 0.22% | 80 |
|
|
2024
Q3 | $3.53M | Buy |
464,048
+63,600
| +16% | +$483K | 0.45% | 60 |
|
|
2024
Q2 | $2.47M | Buy |
+400,448
| New | +$2.47M | 0.33% | 70 |
|
|
2022
Q2 | – | Sell |
-476,978
| Closed | -$7.76M | – | 80 |
|
|
2022
Q1 | $7.76M | Buy |
476,978
+76,977
| +19% | +$1.25M | 2.27% | 17 |
|
|
2021
Q4 | $5.54M | Buy |
400,001
+298,040
| +292% | +$4.13M | 1.22% | 28 |
|
|
2021
Q3 | $1.47M | Sell |
101,961
-250,000
| -71% | -$3.59M | 0.37% | 59 |
|
|
2021
Q2 | $5.57M | Buy |
351,961
+107,281
| +44% | +$1.7M | 1.22% | 31 |
|
|
2021
Q1 | $2.49M | Sell |
244,680
-293,690
| -55% | -$2.99M | 0.58% | 46 |
|
|
2020
Q4 | $4.01M | Sell |
538,370
-262,370
| -33% | -$1.95M | 1.03% | 40 |
|
|
2020
Q3 | $2.75M | Sell |
800,740
-99,868
| -11% | -$343K | 0.73% | 49 |
|
|
2020
Q2 | $4.29M | Sell |
900,608
-95,000
| -10% | -$453K | 1.21% | 32 |
|
|
2020
Q1 | $1.99M | Sell |
995,608
-145,604
| -13% | -$291K | 0.92% | 37 |
|
|
2019
Q4 | $3.94M | Buy |
+1,141,212
| New | +$3.94M | 1.14% | 31 |
|